Abstract
Immune responses can enhance anti-tumor capacity of viruses; therefore, full investigation of oncolytic virotherapy requires use of non-immunodeficient mice. Since no commercial cell lines are available, we established a murine model for oral carcinoma and evaluated oncolytic activity of HF10, naturally attenuated herpes simplex virus, in vitro and in vivo.
| Original language | English |
|---|---|
| Pages (from-to) | 220-227 |
| Number of pages | 8 |
| Journal | Molecular Therapy Oncolytics |
| Volume | 20 |
| DOIs | |
| Publication status | Published - 26-03-2021 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Molecular Medicine
- Oncology
- Cancer Research
- Pharmacology (medical)
Fingerprint
Dive into the research topics of 'Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver